Aytu BioPharma Q4 2026 Earnings Report

Aytu BioPharma EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.22
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Aytu BioPharma Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $17.18 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Aytu BioPharma Announcement Details

• Quarter: Q4 2026
• Date: 9/22/2026
• Time: After Market Closes
• Conference Call Date: Friday, September 25, 2026
• Conference Call Time: 4:00PM ET

Aytu BioPharma (NASDAQ:AYTU), Inc. is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms. The company also offers NeoProfen (ibuprofen lysine injection) for the closure of patent ductus arteriosus in premature infants and markets an FDA-authorized rapid antigen COVID-19 self-test under license. Aytu’s products are generally distributed through specialty pharmacies, hospital networks and national wholesale distributors across the United States.

Under the leadership of President and Chief Executive Officer Josh Disbrow, Aytu continues to explore licensing partnerships and in-licensing opportunities to expand its pipeline. In addition to its commercial business, the company holds exclusive rights to clinical-stage candidates addressing chronic kidney disease and other orphan indications. Aytu’s management team brings experience in life sciences finance, regulatory affairs and commercial operations as it seeks to grow both its therapeutic and diagnostic offerings and extend its reach through strategic collaborations.